- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Press Releases
2013
Chinese Premier Li Keqiang Visits WuXi PharmaTech’s Headquarters in Shanghai
Chinese Premier Li Keqiang Visits WuXi PharmaTech’s Headquarters in Shanghai
SHANGHAI, April 1, 2013 — Chinese Premier Li Keqiang visited WuXi PharmaTech’s headquarters in Shanghai on March 28, 2013. The visit was part of the first research tour by the newly elected Chinese Premier since assuming office in March 2013.
Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, accompanied Premier Li on the tour of research laboratories. “We are very excited to host Premier Li at WuXi,” said Dr. Ge Li. “He always pays close attention to the healthcare industry and the well-being of Chinese people. WuXi will continue to strengthen our platform to enable more companies, organizations and entrepreneurs to discover and develop better therapeutic products for patients.”
Premier Li’s visit highlights WuXi’s leadership in China’s life science industries. It also highlights the role of innovation in fostering the country’s growth and improving quality of life for Chinese patients. China’s strategic investment in healthcare aims to make available more effective and affordable treatments for diseases prevalent in the Chinese population, and WuXi strives to become the partner-of-choice for its global collaborators to bring more innovative products to the fastest growing China healthcare market.